nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—CHEK2—ovarian cancer	0.304	0.892	CbGaD
Sunitinib—ABCB1—ovarian cancer	0.0369	0.108	CbGaD
Sunitinib—ABCG2—Topotecan—ovarian cancer	0.022	0.13	CbGbCtD
Sunitinib—ABCC2—Paclitaxel—ovarian cancer	0.012	0.0711	CbGbCtD
Sunitinib—ABCC2—Carboplatin—ovarian cancer	0.0113	0.0669	CbGbCtD
Sunitinib—ABCG2—Paclitaxel—ovarian cancer	0.0109	0.0643	CbGbCtD
Sunitinib—ABCG2—Carboplatin—ovarian cancer	0.0102	0.0605	CbGbCtD
Sunitinib—ABCC2—Docetaxel—ovarian cancer	0.0087	0.0514	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.00803	0.0475	CbGbCtD
Sunitinib—CYP3A7—Paclitaxel—ovarian cancer	0.00803	0.0475	CbGbCtD
Sunitinib—ABCB1—Topotecan—ovarian cancer	0.00792	0.0468	CbGbCtD
Sunitinib—ABCG2—Docetaxel—ovarian cancer	0.00786	0.0465	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—ovarian cancer	0.00648	0.0383	CbGbCtD
Sunitinib—CYP3A5—Paclitaxel—ovarian cancer	0.00602	0.0356	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—ovarian cancer	0.00586	0.0346	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.00581	0.0343	CbGbCtD
Sunitinib—CYP3A7—Docetaxel—ovarian cancer	0.00581	0.0343	CbGbCtD
Sunitinib—ABCB1—Vinorelbine—ovarian cancer	0.00558	0.033	CbGbCtD
Sunitinib—CYP3A4—Topotecan—ovarian cancer	0.00475	0.0281	CbGbCtD
Sunitinib—CYP3A5—Docetaxel—ovarian cancer	0.00436	0.0258	CbGbCtD
Sunitinib—ABCB1—Paclitaxel—ovarian cancer	0.00392	0.0232	CbGbCtD
Sunitinib—CYP3A4—Vinorelbine—ovarian cancer	0.00334	0.0198	CbGbCtD
Sunitinib—ABCB1—Docetaxel—ovarian cancer	0.00283	0.0168	CbGbCtD
Sunitinib—CYP3A4—Paclitaxel—ovarian cancer	0.00235	0.0139	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—ovarian cancer	0.00211	0.0125	CbGbCtD
Sunitinib—CYP3A4—Docetaxel—ovarian cancer	0.0017	0.01	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—ovarian cancer	0.00127	0.00749	CbGbCtD
Sunitinib—ROCK1—Irinotecan—Topotecan—ovarian cancer	0.000863	0.222	CbGdCrCtD
Sunitinib—MAP4K4—Irinotecan—Topotecan—ovarian cancer	0.000769	0.198	CbGdCrCtD
Sunitinib—TLK2—Irinotecan—Topotecan—ovarian cancer	0.000654	0.168	CbGdCrCtD
Sunitinib—CHEK2—Docetaxel—Paclitaxel—ovarian cancer	0.000252	0.0649	CbGdCrCtD
Sunitinib—CHEK2—Vindesine—Vinorelbine—ovarian cancer	0.00016	0.0413	CbGdCrCtD
Sunitinib—CHEK2—Paclitaxel—Docetaxel—ovarian cancer	0.000126	0.0324	CbGdCrCtD
Sunitinib—TBK1—female gonad—ovarian cancer	9.89e-05	0.000679	CbGeAlD
Sunitinib—FGFR2—female reproductive system—ovarian cancer	9.87e-05	0.000678	CbGeAlD
Sunitinib—RPS6KB1—bone marrow—ovarian cancer	9.87e-05	0.000678	CbGeAlD
Sunitinib—STK39—lymph node—ovarian cancer	9.87e-05	0.000678	CbGeAlD
Sunitinib—BMP2K—testis—ovarian cancer	9.86e-05	0.000677	CbGeAlD
Sunitinib—CAMK2G—testis—ovarian cancer	9.86e-05	0.000677	CbGeAlD
Sunitinib—KDR—decidua—ovarian cancer	9.84e-05	0.000676	CbGeAlD
Sunitinib—MAP2K5—decidua—ovarian cancer	9.84e-05	0.000676	CbGeAlD
Sunitinib—TBK1—vagina—ovarian cancer	9.83e-05	0.000675	CbGeAlD
Sunitinib—TYK2—female gonad—ovarian cancer	9.82e-05	0.000675	CbGeAlD
Sunitinib—JAK2—female reproductive system—ovarian cancer	9.82e-05	0.000675	CbGeAlD
Sunitinib—FGR—bone marrow—ovarian cancer	9.81e-05	0.000674	CbGeAlD
Sunitinib—YES1—gonad—ovarian cancer	9.79e-05	0.000672	CbGeAlD
Sunitinib—LRRK2—testis—ovarian cancer	9.77e-05	0.000671	CbGeAlD
Sunitinib—TYK2—vagina—ovarian cancer	9.76e-05	0.000671	CbGeAlD
Sunitinib—CSNK2A1—lymph node—ovarian cancer	9.74e-05	0.000669	CbGeAlD
Sunitinib—YES1—uterus—ovarian cancer	9.72e-05	0.000668	CbGeAlD
Sunitinib—STK10—gonad—ovarian cancer	9.7e-05	0.000666	CbGeAlD
Sunitinib—IRAK1—female gonad—ovarian cancer	9.7e-05	0.000666	CbGeAlD
Sunitinib—FYN—female reproductive system—ovarian cancer	9.69e-05	0.000665	CbGeAlD
Sunitinib—STK10—uterus—ovarian cancer	9.64e-05	0.000662	CbGeAlD
Sunitinib—PRKAA1—testis—ovarian cancer	9.63e-05	0.000662	CbGeAlD
Sunitinib—MYLK—lymph node—ovarian cancer	9.61e-05	0.00066	CbGeAlD
Sunitinib—PDGFRA—gonad—ovarian cancer	9.6e-05	0.00066	CbGeAlD
Sunitinib—CSF1R—decidua—ovarian cancer	9.6e-05	0.000659	CbGeAlD
Sunitinib—TAOK3—uterus—ovarian cancer	9.6e-05	0.000659	CbGeAlD
Sunitinib—PDGFRA—uterus—ovarian cancer	9.54e-05	0.000655	CbGeAlD
Sunitinib—PTK2B—testis—ovarian cancer	9.53e-05	0.000654	CbGeAlD
Sunitinib—RPS6KB1—female gonad—ovarian cancer	9.51e-05	0.000653	CbGeAlD
Sunitinib—FLT4—testis—ovarian cancer	9.5e-05	0.000652	CbGeAlD
Sunitinib—PLK4—lymph node—ovarian cancer	9.49e-05	0.000652	CbGeAlD
Sunitinib—MAP3K3—female reproductive system—ovarian cancer	9.47e-05	0.00065	CbGeAlD
Sunitinib—MAP4K5—female reproductive system—ovarian cancer	9.47e-05	0.00065	CbGeAlD
Sunitinib—RPS6KB1—vagina—ovarian cancer	9.46e-05	0.000649	CbGeAlD
Sunitinib—FGR—female gonad—ovarian cancer	9.46e-05	0.000649	CbGeAlD
Sunitinib—STK4—lymph node—ovarian cancer	9.43e-05	0.000648	CbGeAlD
Sunitinib—AXL—female gonad—ovarian cancer	9.42e-05	0.000647	CbGeAlD
Sunitinib—SLK—bone marrow—ovarian cancer	9.41e-05	0.000646	CbGeAlD
Sunitinib—FGR—vagina—ovarian cancer	9.4e-05	0.000646	CbGeAlD
Sunitinib—CSNK1E—testis—ovarian cancer	9.37e-05	0.000644	CbGeAlD
Sunitinib—FGFR1—testis—ovarian cancer	9.37e-05	0.000644	CbGeAlD
Sunitinib—AXL—vagina—ovarian cancer	9.36e-05	0.000643	CbGeAlD
Sunitinib—KDR—endometrium—ovarian cancer	9.34e-05	0.000641	CbGeAlD
Sunitinib—MAP2K5—endometrium—ovarian cancer	9.34e-05	0.000641	CbGeAlD
Sunitinib—JAK2—bone marrow—ovarian cancer	9.27e-05	0.000637	CbGeAlD
Sunitinib—PHKG2—lymph node—ovarian cancer	9.27e-05	0.000637	CbGeAlD
Sunitinib—KIT—epithelium—ovarian cancer	9.23e-05	0.000634	CbGeAlD
Sunitinib—IRAK4—testis—ovarian cancer	9.23e-05	0.000634	CbGeAlD
Sunitinib—STK24—lymph node—ovarian cancer	9.21e-05	0.000633	CbGeAlD
Sunitinib—FLT1—female reproductive system—ovarian cancer	9.15e-05	0.000629	CbGeAlD
Sunitinib—KIT—uterine cervix—ovarian cancer	9.15e-05	0.000629	CbGeAlD
Sunitinib—FYN—bone marrow—ovarian cancer	9.15e-05	0.000628	CbGeAlD
Sunitinib—CSF1R—endometrium—ovarian cancer	9.11e-05	0.000626	CbGeAlD
Sunitinib—DAPK2—lymph node—ovarian cancer	9.11e-05	0.000626	CbGeAlD
Sunitinib—SLK—female gonad—ovarian cancer	9.07e-05	0.000623	CbGeAlD
Sunitinib—MAP2K2—testis—ovarian cancer	9.02e-05	0.00062	CbGeAlD
Sunitinib—ULK3—testis—ovarian cancer	9.02e-05	0.00062	CbGeAlD
Sunitinib—PDGFRB—epithelium—ovarian cancer	9.01e-05	0.000619	CbGeAlD
Sunitinib—SLK—vagina—ovarian cancer	9.01e-05	0.000619	CbGeAlD
Sunitinib—FGFR2—female gonad—ovarian cancer	8.98e-05	0.000617	CbGeAlD
Sunitinib—STK16—lymph node—ovarian cancer	8.96e-05	0.000616	CbGeAlD
Sunitinib—MAP3K2—testis—ovarian cancer	8.96e-05	0.000615	CbGeAlD
Sunitinib—PDGFRB—uterine cervix—ovarian cancer	8.94e-05	0.000614	CbGeAlD
Sunitinib—JAK2—female gonad—ovarian cancer	8.94e-05	0.000614	CbGeAlD
Sunitinib—MAP4K5—bone marrow—ovarian cancer	8.94e-05	0.000614	CbGeAlD
Sunitinib—MAP3K3—bone marrow—ovarian cancer	8.94e-05	0.000614	CbGeAlD
Sunitinib—HIPK2—lymph node—ovarian cancer	8.92e-05	0.000612	CbGeAlD
Sunitinib—HIPK3—lymph node—ovarian cancer	8.92e-05	0.000612	CbGeAlD
Sunitinib—ALK—lymph node—ovarian cancer	8.92e-05	0.000612	CbGeAlD
Sunitinib—JAK2—vagina—ovarian cancer	8.88e-05	0.00061	CbGeAlD
Sunitinib—MAP3K7—testis—ovarian cancer	8.87e-05	0.000609	CbGeAlD
Sunitinib—RIOK2—lymph node—ovarian cancer	8.82e-05	0.000606	CbGeAlD
Sunitinib—TNK1—lymph node—ovarian cancer	8.82e-05	0.000606	CbGeAlD
Sunitinib—FYN—female gonad—ovarian cancer	8.81e-05	0.000605	CbGeAlD
Sunitinib—TBK1—testis—ovarian cancer	8.77e-05	0.000602	CbGeAlD
Sunitinib—FYN—vagina—ovarian cancer	8.76e-05	0.000602	CbGeAlD
Sunitinib—YES1—female reproductive system—ovarian cancer	8.74e-05	0.0006	CbGeAlD
Sunitinib—MAP4K1—lymph node—ovarian cancer	8.73e-05	0.0006	CbGeAlD
Sunitinib—KIT—decidua—ovarian cancer	8.72e-05	0.000599	CbGeAlD
Sunitinib—TYK2—testis—ovarian cancer	8.71e-05	0.000598	CbGeAlD
Sunitinib—STK10—female reproductive system—ovarian cancer	8.66e-05	0.000595	CbGeAlD
Sunitinib—CHEK2—Vincristine—Vinorelbine—ovarian cancer	8.65e-05	0.0223	CbGdCrCtD
Sunitinib—TAOK3—female reproductive system—ovarian cancer	8.63e-05	0.000593	CbGeAlD
Sunitinib—MAP4K5—female gonad—ovarian cancer	8.61e-05	0.000592	CbGeAlD
Sunitinib—MAP3K3—female gonad—ovarian cancer	8.61e-05	0.000592	CbGeAlD
Sunitinib—KDR—uterus—ovarian cancer	8.61e-05	0.000591	CbGeAlD
Sunitinib—IRAK1—testis—ovarian cancer	8.6e-05	0.000591	CbGeAlD
Sunitinib—PDGFRA—female reproductive system—ovarian cancer	8.58e-05	0.000589	CbGeAlD
Sunitinib—DAPK3—lymph node—ovarian cancer	8.57e-05	0.000588	CbGeAlD
Sunitinib—MAP3K3—vagina—ovarian cancer	8.56e-05	0.000588	CbGeAlD
Sunitinib—MAP4K5—vagina—ovarian cancer	8.56e-05	0.000588	CbGeAlD
Sunitinib—PDGFRB—decidua—ovarian cancer	8.52e-05	0.000585	CbGeAlD
Sunitinib—CLK2—lymph node—ovarian cancer	8.49e-05	0.000583	CbGeAlD
Sunitinib—CSF1R—gonad—ovarian cancer	8.45e-05	0.000581	CbGeAlD
Sunitinib—MAP4K2—lymph node—ovarian cancer	8.45e-05	0.00058	CbGeAlD
Sunitinib—RPS6KB1—testis—ovarian cancer	8.44e-05	0.00058	CbGeAlD
Sunitinib—CSF1R—uterus—ovarian cancer	8.4e-05	0.000577	CbGeAlD
Sunitinib—FGR—testis—ovarian cancer	8.39e-05	0.000576	CbGeAlD
Sunitinib—RET—testis—ovarian cancer	8.39e-05	0.000576	CbGeAlD
Sunitinib—AXL—testis—ovarian cancer	8.35e-05	0.000574	CbGeAlD
Sunitinib—STK3—lymph node—ovarian cancer	8.33e-05	0.000572	CbGeAlD
Sunitinib—FLT1—female gonad—ovarian cancer	8.33e-05	0.000572	CbGeAlD
Sunitinib—FLT1—vagina—ovarian cancer	8.28e-05	0.000569	CbGeAlD
Sunitinib—KIT—endometrium—ovarian cancer	8.28e-05	0.000568	CbGeAlD
Sunitinib—YES1—bone marrow—ovarian cancer	8.25e-05	0.000567	CbGeAlD
Sunitinib—EPHB6—female gonad—ovarian cancer	8.23e-05	0.000565	CbGeAlD
Sunitinib—EPHB6—vagina—ovarian cancer	8.18e-05	0.000562	CbGeAlD
Sunitinib—STK10—bone marrow—ovarian cancer	8.18e-05	0.000562	CbGeAlD
Sunitinib—TAOK3—bone marrow—ovarian cancer	8.15e-05	0.00056	CbGeAlD
Sunitinib—PDGFRB—endometrium—ovarian cancer	8.08e-05	0.000555	CbGeAlD
Sunitinib—SLK—testis—ovarian cancer	8.04e-05	0.000552	CbGeAlD
Sunitinib—DYRK1A—lymph node—ovarian cancer	8.02e-05	0.000551	CbGeAlD
Sunitinib—FGFR2—testis—ovarian cancer	7.97e-05	0.000547	CbGeAlD
Sunitinib—YES1—female gonad—ovarian cancer	7.95e-05	0.000546	CbGeAlD
Sunitinib—JAK2—testis—ovarian cancer	7.93e-05	0.000544	CbGeAlD
Sunitinib—YES1—vagina—ovarian cancer	7.91e-05	0.000543	CbGeAlD
Sunitinib—STK10—female gonad—ovarian cancer	7.88e-05	0.000541	CbGeAlD
Sunitinib—TAOK3—female gonad—ovarian cancer	7.85e-05	0.000539	CbGeAlD
Sunitinib—STK10—vagina—ovarian cancer	7.84e-05	0.000538	CbGeAlD
Sunitinib—MERTK—lymph node—ovarian cancer	7.83e-05	0.000538	CbGeAlD
Sunitinib—FYN—testis—ovarian cancer	7.82e-05	0.000537	CbGeAlD
Sunitinib—TAOK3—vagina—ovarian cancer	7.81e-05	0.000536	CbGeAlD
Sunitinib—PDGFRA—female gonad—ovarian cancer	7.8e-05	0.000536	CbGeAlD
Sunitinib—PDGFRA—vagina—ovarian cancer	7.76e-05	0.000533	CbGeAlD
Sunitinib—KDR—female reproductive system—ovarian cancer	7.74e-05	0.000531	CbGeAlD
Sunitinib—MAP2K5—female reproductive system—ovarian cancer	7.74e-05	0.000531	CbGeAlD
Sunitinib—MAP4K4—lymph node—ovarian cancer	7.69e-05	0.000528	CbGeAlD
Sunitinib—KIT—gonad—ovarian cancer	7.68e-05	0.000527	CbGeAlD
Sunitinib—MAP3K3—testis—ovarian cancer	7.64e-05	0.000525	CbGeAlD
Sunitinib—MAP4K5—testis—ovarian cancer	7.64e-05	0.000525	CbGeAlD
Sunitinib—NUAK2—lymph node—ovarian cancer	7.63e-05	0.000524	CbGeAlD
Sunitinib—KIT—uterus—ovarian cancer	7.63e-05	0.000524	CbGeAlD
Sunitinib—FLT3—lymph node—ovarian cancer	7.58e-05	0.000521	CbGeAlD
Sunitinib—MAP3K12—lymph node—ovarian cancer	7.58e-05	0.000521	CbGeAlD
Sunitinib—CSF1R—female reproductive system—ovarian cancer	7.55e-05	0.000519	CbGeAlD
Sunitinib—PDGFRB—gonad—ovarian cancer	7.5e-05	0.000515	CbGeAlD
Sunitinib—RPS6KA3—lymph node—ovarian cancer	7.48e-05	0.000514	CbGeAlD
Sunitinib—PDGFRB—uterus—ovarian cancer	7.45e-05	0.000512	CbGeAlD
Sunitinib—MAP2K1—lymph node—ovarian cancer	7.43e-05	0.00051	CbGeAlD
Sunitinib—FLT1—testis—ovarian cancer	7.39e-05	0.000507	CbGeAlD
Sunitinib—CSNK1A1—lymph node—ovarian cancer	7.33e-05	0.000504	CbGeAlD
Sunitinib—KDR—bone marrow—ovarian cancer	7.3e-05	0.000502	CbGeAlD
Sunitinib—EPHB6—testis—ovarian cancer	7.3e-05	0.000501	CbGeAlD
Sunitinib—CLK1—lymph node—ovarian cancer	7.28e-05	0.0005	CbGeAlD
Sunitinib—KCNH2—myometrium—ovarian cancer	7.26e-05	0.000498	CbGeAlD
Sunitinib—CAMK2G—lymph node—ovarian cancer	7.15e-05	0.000491	CbGeAlD
Sunitinib—BMP2K—lymph node—ovarian cancer	7.15e-05	0.000491	CbGeAlD
Sunitinib—CSF1R—bone marrow—ovarian cancer	7.13e-05	0.00049	CbGeAlD
Sunitinib—LRRK2—lymph node—ovarian cancer	7.09e-05	0.000487	CbGeAlD
Sunitinib—YES1—testis—ovarian cancer	7.06e-05	0.000485	CbGeAlD
Sunitinib—KDR—female gonad—ovarian cancer	7.04e-05	0.000484	CbGeAlD
Sunitinib—MAP2K5—female gonad—ovarian cancer	7.04e-05	0.000484	CbGeAlD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—ovarian cancer	7e-05	0.018	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—ovarian cancer	7e-05	0.018	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—ovarian cancer	7e-05	0.018	CbGdCrCtD
Sunitinib—KDR—vagina—ovarian cancer	7e-05	0.000481	CbGeAlD
Sunitinib—MAP2K5—vagina—ovarian cancer	7e-05	0.000481	CbGeAlD
Sunitinib—STK10—testis—ovarian cancer	6.99e-05	0.00048	CbGeAlD
Sunitinib—PRKAA1—lymph node—ovarian cancer	6.98e-05	0.00048	CbGeAlD
Sunitinib—TAOK3—testis—ovarian cancer	6.96e-05	0.000478	CbGeAlD
Sunitinib—CHEK2—Vinblastine—Vinorelbine—ovarian cancer	6.96e-05	0.0179	CbGdCrCtD
Sunitinib—PDGFRA—testis—ovarian cancer	6.92e-05	0.000475	CbGeAlD
Sunitinib—PTK2B—lymph node—ovarian cancer	6.9e-05	0.000474	CbGeAlD
Sunitinib—FLT4—lymph node—ovarian cancer	6.89e-05	0.000473	CbGeAlD
Sunitinib—CSF1R—female gonad—ovarian cancer	6.87e-05	0.000472	CbGeAlD
Sunitinib—KIT—female reproductive system—ovarian cancer	6.86e-05	0.000471	CbGeAlD
Sunitinib—CSF1R—vagina—ovarian cancer	6.83e-05	0.000469	CbGeAlD
Sunitinib—CSNK1E—lymph node—ovarian cancer	6.79e-05	0.000467	CbGeAlD
Sunitinib—FGFR1—lymph node—ovarian cancer	6.79e-05	0.000467	CbGeAlD
Sunitinib—PDGFRB—female reproductive system—ovarian cancer	6.7e-05	0.00046	CbGeAlD
Sunitinib—IRAK4—lymph node—ovarian cancer	6.69e-05	0.000459	CbGeAlD
Sunitinib—MAP2K2—lymph node—ovarian cancer	6.54e-05	0.000449	CbGeAlD
Sunitinib—ULK3—lymph node—ovarian cancer	6.54e-05	0.000449	CbGeAlD
Sunitinib—MAP3K2—lymph node—ovarian cancer	6.49e-05	0.000446	CbGeAlD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—ovarian cancer	6.48e-05	0.0167	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—ovarian cancer	6.48e-05	0.0167	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—ovarian cancer	6.48e-05	0.0167	CbGdCrCtD
Sunitinib—KIT—bone marrow—ovarian cancer	6.47e-05	0.000445	CbGeAlD
Sunitinib—ABCG2—myometrium—ovarian cancer	6.46e-05	0.000443	CbGeAlD
Sunitinib—MAP3K7—lymph node—ovarian cancer	6.43e-05	0.000442	CbGeAlD
Sunitinib—TBK1—lymph node—ovarian cancer	6.36e-05	0.000437	CbGeAlD
Sunitinib—PDGFRB—bone marrow—ovarian cancer	6.32e-05	0.000434	CbGeAlD
Sunitinib—TYK2—lymph node—ovarian cancer	6.32e-05	0.000434	CbGeAlD
Sunitinib—MAP2K5—testis—ovarian cancer	6.24e-05	0.000429	CbGeAlD
Sunitinib—KDR—testis—ovarian cancer	6.24e-05	0.000429	CbGeAlD
Sunitinib—KIT—female gonad—ovarian cancer	6.24e-05	0.000429	CbGeAlD
Sunitinib—IRAK1—lymph node—ovarian cancer	6.23e-05	0.000428	CbGeAlD
Sunitinib—KIT—vagina—ovarian cancer	6.2e-05	0.000426	CbGeAlD
Sunitinib—RPS6KB1—lymph node—ovarian cancer	6.12e-05	0.00042	CbGeAlD
Sunitinib—CSF1R—testis—ovarian cancer	6.09e-05	0.000419	CbGeAlD
Sunitinib—PDGFRB—female gonad—ovarian cancer	6.09e-05	0.000419	CbGeAlD
Sunitinib—RET—lymph node—ovarian cancer	6.08e-05	0.000418	CbGeAlD
Sunitinib—FGR—lymph node—ovarian cancer	6.08e-05	0.000418	CbGeAlD
Sunitinib—PDGFRB—vagina—ovarian cancer	6.06e-05	0.000416	CbGeAlD
Sunitinib—AXL—lymph node—ovarian cancer	6.05e-05	0.000416	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—ovarian cancer	6.04e-05	0.0156	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—ovarian cancer	6.04e-05	0.0156	CbGdCrCtD
Sunitinib—ABCC4—uterus—ovarian cancer	5.93e-05	0.000407	CbGeAlD
Sunitinib—Dry skin—Doxorubicin—ovarian cancer	5.85e-05	0.000408	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—ovarian cancer	5.85e-05	0.000408	CcSEcCtD
Sunitinib—Shock—Paclitaxel—ovarian cancer	5.84e-05	0.000407	CcSEcCtD
Sunitinib—Dizziness—Vinorelbine—ovarian cancer	5.83e-05	0.000407	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—ovarian cancer	5.83e-05	0.000407	CcSEcCtD
Sunitinib—SLK—lymph node—ovarian cancer	5.83e-05	0.0004	CbGeAlD
Sunitinib—Nervous system disorder—Paclitaxel—ovarian cancer	5.82e-05	0.000406	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—ovarian cancer	5.81e-05	0.000405	CcSEcCtD
Sunitinib—Thrombocytopenia—Paclitaxel—ovarian cancer	5.81e-05	0.000405	CcSEcCtD
Sunitinib—Skin disorder—Paclitaxel—ovarian cancer	5.76e-05	0.000402	CcSEcCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	5.75e-05	0.000401	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	5.75e-05	0.000401	CcSEcCtD
Sunitinib—JAK2—lymph node—ovarian cancer	5.75e-05	0.000395	CbGeAlD
Sunitinib—Bronchitis—Epirubicin—ovarian cancer	5.74e-05	0.0004	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—ovarian cancer	5.71e-05	0.000398	CcSEcCtD
Sunitinib—Anaemia—Docetaxel—ovarian cancer	5.7e-05	0.000397	CcSEcCtD
Sunitinib—FYN—lymph node—ovarian cancer	5.67e-05	0.000389	CbGeAlD
Sunitinib—Pancytopenia—Epirubicin—ovarian cancer	5.67e-05	0.000395	CcSEcCtD
Sunitinib—Anorexia—Paclitaxel—ovarian cancer	5.66e-05	0.000394	CcSEcCtD
Sunitinib—KCNH2—uterine cervix—ovarian cancer	5.65e-05	0.000388	CbGeAlD
Sunitinib—Muscular weakness—Doxorubicin—ovarian cancer	5.63e-05	0.000393	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	5.63e-05	0.000393	CcSEcCtD
Sunitinib—Vomiting—Vinorelbine—ovarian cancer	5.61e-05	0.000391	CcSEcCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—ovarian cancer	5.59e-05	0.0144	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—ovarian cancer	5.59e-05	0.0144	CbGdCrCtD
Sunitinib—Neutropenia—Epirubicin—ovarian cancer	5.58e-05	0.000389	CcSEcCtD
Sunitinib—Rash—Vinorelbine—ovarian cancer	5.56e-05	0.000388	CcSEcCtD
Sunitinib—Dermatitis—Vinorelbine—ovarian cancer	5.56e-05	0.000387	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—ovarian cancer	5.56e-05	0.000387	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—ovarian cancer	5.54e-05	0.000386	CcSEcCtD
Sunitinib—MAP4K5—lymph node—ovarian cancer	5.54e-05	0.00038	CbGeAlD
Sunitinib—MAP3K3—lymph node—ovarian cancer	5.54e-05	0.00038	CbGeAlD
Sunitinib—KIT—testis—ovarian cancer	5.53e-05	0.00038	CbGeAlD
Sunitinib—Headache—Vinorelbine—ovarian cancer	5.53e-05	0.000385	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—ovarian cancer	5.52e-05	0.000385	CcSEcCtD
Sunitinib—Leukopenia—Docetaxel—ovarian cancer	5.52e-05	0.000384	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—ovarian cancer	5.41e-05	0.000377	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	5.41e-05	0.000377	CcSEcCtD
Sunitinib—PDGFRB—testis—ovarian cancer	5.4e-05	0.000371	CbGeAlD
Sunitinib—Weight decreased—Epirubicin—ovarian cancer	5.4e-05	0.000376	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—ovarian cancer	5.38e-05	0.000375	CcSEcCtD
Sunitinib—Cough—Docetaxel—ovarian cancer	5.38e-05	0.000375	CcSEcCtD
Sunitinib—Insomnia—Paclitaxel—ovarian cancer	5.37e-05	0.000374	CcSEcCtD
Sunitinib—FLT1—lymph node—ovarian cancer	5.35e-05	0.000368	CbGeAlD
Sunitinib—Pneumonia—Epirubicin—ovarian cancer	5.35e-05	0.000373	CcSEcCtD
Sunitinib—Convulsion—Docetaxel—ovarian cancer	5.34e-05	0.000372	CcSEcCtD
Sunitinib—ABCC4—female reproductive system—ovarian cancer	5.33e-05	0.000366	CbGeAlD
Sunitinib—Paraesthesia—Paclitaxel—ovarian cancer	5.33e-05	0.000371	CcSEcCtD
Sunitinib—Hypertension—Docetaxel—ovarian cancer	5.32e-05	0.000371	CcSEcCtD
Sunitinib—Infestation NOS—Epirubicin—ovarian cancer	5.32e-05	0.000371	CcSEcCtD
Sunitinib—Infestation—Epirubicin—ovarian cancer	5.32e-05	0.000371	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—ovarian cancer	5.31e-05	0.00037	CcSEcCtD
Sunitinib—EPHB6—lymph node—ovarian cancer	5.29e-05	0.000364	CbGeAlD
Sunitinib—Dyspnoea—Paclitaxel—ovarian cancer	5.29e-05	0.000369	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	5.27e-05	0.000368	CcSEcCtD
Sunitinib—Myalgia—Docetaxel—ovarian cancer	5.25e-05	0.000366	CcSEcCtD
Sunitinib—Arthralgia—Docetaxel—ovarian cancer	5.25e-05	0.000366	CcSEcCtD
Sunitinib—Chest pain—Docetaxel—ovarian cancer	5.25e-05	0.000366	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—ovarian cancer	5.24e-05	0.000365	CcSEcCtD
Sunitinib—Nausea—Vinorelbine—ovarian cancer	5.24e-05	0.000365	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—ovarian cancer	5.23e-05	0.000364	CcSEcCtD
Sunitinib—Dyspepsia—Paclitaxel—ovarian cancer	5.22e-05	0.000364	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—ovarian cancer	5.21e-05	0.000363	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	5.21e-05	0.000363	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—ovarian cancer	5.18e-05	0.000361	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—ovarian cancer	5.17e-05	0.00036	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—ovarian cancer	5.16e-05	0.00036	CcSEcCtD
Sunitinib—ABCC2—female reproductive system—ovarian cancer	5.16e-05	0.000355	CbGeAlD
Sunitinib—Decreased appetite—Paclitaxel—ovarian cancer	5.16e-05	0.00036	CcSEcCtD
Sunitinib—Dry mouth—Docetaxel—ovarian cancer	5.13e-05	0.000358	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	5.13e-05	0.000358	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	5.12e-05	0.000357	CcSEcCtD
Sunitinib—Fatigue—Paclitaxel—ovarian cancer	5.12e-05	0.000357	CcSEcCtD
Sunitinib—YES1—lymph node—ovarian cancer	5.11e-05	0.000351	CbGeAlD
Sunitinib—KCNH2—endometrium—ovarian cancer	5.11e-05	0.000351	CbGeAlD
Sunitinib—Pain—Paclitaxel—ovarian cancer	5.07e-05	0.000354	CcSEcCtD
Sunitinib—Constipation—Paclitaxel—ovarian cancer	5.07e-05	0.000354	CcSEcCtD
Sunitinib—STK10—lymph node—ovarian cancer	5.07e-05	0.000348	CbGeAlD
Sunitinib—TAOK3—lymph node—ovarian cancer	5.05e-05	0.000347	CbGeAlD
Sunitinib—ABCC4—bone marrow—ovarian cancer	5.03e-05	0.000346	CbGeAlD
Sunitinib—Hepatobiliary disease—Epirubicin—ovarian cancer	5.03e-05	0.000351	CcSEcCtD
Sunitinib—Oedema—Docetaxel—ovarian cancer	5.03e-05	0.000351	CcSEcCtD
Sunitinib—ABCG2—uterine cervix—ovarian cancer	5.02e-05	0.000345	CbGeAlD
Sunitinib—PDGFRA—lymph node—ovarian cancer	5.02e-05	0.000345	CbGeAlD
Sunitinib—Epistaxis—Epirubicin—ovarian cancer	5.02e-05	0.00035	CcSEcCtD
Sunitinib—Infection—Docetaxel—ovarian cancer	5e-05	0.000348	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—ovarian cancer	4.99e-05	0.000348	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—ovarian cancer	4.98e-05	0.000347	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—ovarian cancer	4.95e-05	0.000345	CcSEcCtD
Sunitinib—Shock—Docetaxel—ovarian cancer	4.95e-05	0.000345	CcSEcCtD
Sunitinib—Nervous system disorder—Docetaxel—ovarian cancer	4.93e-05	0.000344	CcSEcCtD
Sunitinib—Thrombocytopenia—Docetaxel—ovarian cancer	4.92e-05	0.000343	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—ovarian cancer	4.92e-05	0.000343	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—ovarian cancer	4.92e-05	0.000343	CcSEcCtD
Sunitinib—Skin disorder—Docetaxel—ovarian cancer	4.89e-05	0.000341	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	4.88e-05	0.00034	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—ovarian cancer	4.86e-05	0.000339	CcSEcCtD
Sunitinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	4.85e-05	0.000338	CcSEcCtD
Sunitinib—ABCC4—female gonad—ovarian cancer	4.85e-05	0.000333	CbGeAlD
Sunitinib—Renal failure—Doxorubicin—ovarian cancer	4.84e-05	0.000337	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	4.82e-05	0.000336	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—ovarian cancer	4.8e-05	0.000335	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—ovarian cancer	4.8e-05	0.000334	CcSEcCtD
Sunitinib—Anorexia—Docetaxel—ovarian cancer	4.79e-05	0.000334	CcSEcCtD
Sunitinib—ABCG2—decidua—ovarian cancer	4.79e-05	0.000329	CbGeAlD
Sunitinib—Urinary tract infection—Doxorubicin—ovarian cancer	4.78e-05	0.000333	CcSEcCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—ovarian cancer	4.78e-05	0.0123	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—ovarian cancer	4.78e-05	0.0123	CbGdCrCtD
Sunitinib—Haemorrhage—Epirubicin—ovarian cancer	4.77e-05	0.000333	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—ovarian cancer	4.77e-05	0.000333	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—ovarian cancer	4.75e-05	0.000331	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—ovarian cancer	4.72e-05	0.000329	CcSEcCtD
Sunitinib—KCNH2—uterus—ovarian cancer	4.71e-05	0.000323	CbGeAlD
Sunitinib—Oedema peripheral—Epirubicin—ovarian cancer	4.7e-05	0.000328	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—ovarian cancer	4.69e-05	0.000327	CcSEcCtD
Sunitinib—Body temperature increased—Paclitaxel—ovarian cancer	4.69e-05	0.000327	CcSEcCtD
Sunitinib—Abdominal pain—Paclitaxel—ovarian cancer	4.69e-05	0.000327	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—ovarian cancer	4.68e-05	0.000326	CcSEcCtD
Sunitinib—CYP3A5—uterine cervix—ovarian cancer	4.66e-05	0.00032	CbGeAlD
Sunitinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	4.65e-05	0.000324	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—ovarian cancer	4.64e-05	0.000324	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	4.58e-05	0.000319	CcSEcCtD
Sunitinib—Insomnia—Docetaxel—ovarian cancer	4.55e-05	0.000317	CcSEcCtD
Sunitinib—ABCG2—endometrium—ovarian cancer	4.54e-05	0.000312	CbGeAlD
Sunitinib—KDR—lymph node—ovarian cancer	4.53e-05	0.000311	CbGeAlD
Sunitinib—MAP2K5—lymph node—ovarian cancer	4.53e-05	0.000311	CbGeAlD
Sunitinib—Paraesthesia—Docetaxel—ovarian cancer	4.52e-05	0.000315	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—ovarian cancer	4.51e-05	0.000315	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—ovarian cancer	4.5e-05	0.000314	CcSEcCtD
Sunitinib—Dyspnoea—Docetaxel—ovarian cancer	4.48e-05	0.000313	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—ovarian cancer	4.46e-05	0.000311	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—ovarian cancer	4.44e-05	0.00031	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—ovarian cancer	4.43e-05	0.000309	CcSEcCtD
Sunitinib—Flushing—Epirubicin—ovarian cancer	4.43e-05	0.000309	CcSEcCtD
Sunitinib—Dyspepsia—Docetaxel—ovarian cancer	4.43e-05	0.000309	CcSEcCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—ovarian cancer	4.42e-05	0.0114	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—ovarian cancer	4.42e-05	0.0114	CbGdCrCtD
Sunitinib—Haemorrhage—Doxorubicin—ovarian cancer	4.42e-05	0.000308	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—ovarian cancer	4.42e-05	0.000308	CcSEcCtD
Sunitinib—CSF1R—lymph node—ovarian cancer	4.42e-05	0.000303	CbGeAlD
Sunitinib—Hypoaesthesia—Doxorubicin—ovarian cancer	4.4e-05	0.000306	CcSEcCtD
Sunitinib—Decreased appetite—Docetaxel—ovarian cancer	4.37e-05	0.000305	CcSEcCtD
Sunitinib—Hypersensitivity—Paclitaxel—ovarian cancer	4.37e-05	0.000305	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—ovarian cancer	4.36e-05	0.000304	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—ovarian cancer	4.35e-05	0.000303	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	4.34e-05	0.000303	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—ovarian cancer	4.34e-05	0.000303	CcSEcCtD
Sunitinib—Fatigue—Docetaxel—ovarian cancer	4.34e-05	0.000302	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—ovarian cancer	4.33e-05	0.000302	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—ovarian cancer	4.33e-05	0.000302	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—ovarian cancer	4.31e-05	0.000301	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—ovarian cancer	4.3e-05	0.0003	CcSEcCtD
Sunitinib—ABCC4—testis—ovarian cancer	4.3e-05	0.000296	CbGeAlD
Sunitinib—Constipation—Docetaxel—ovarian cancer	4.3e-05	0.0003	CcSEcCtD
Sunitinib—Pain—Docetaxel—ovarian cancer	4.3e-05	0.0003	CcSEcCtD
Sunitinib—Chills—Epirubicin—ovarian cancer	4.28e-05	0.000299	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—ovarian cancer	4.27e-05	0.000297	CcSEcCtD
Sunitinib—Asthenia—Paclitaxel—ovarian cancer	4.26e-05	0.000297	CcSEcCtD
Sunitinib—KCNH2—female reproductive system—ovarian cancer	4.23e-05	0.000291	CbGeAlD
Sunitinib—Alopecia—Epirubicin—ovarian cancer	4.22e-05	0.000294	CcSEcCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—ovarian cancer	4.21e-05	0.0109	CbGdCrCtD
Sunitinib—Pruritus—Paclitaxel—ovarian cancer	4.2e-05	0.000293	CcSEcCtD
Sunitinib—ABCG2—uterus—ovarian cancer	4.19e-05	0.000288	CbGeAlD
Sunitinib—Mental disorder—Epirubicin—ovarian cancer	4.18e-05	0.000292	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—ovarian cancer	4.18e-05	0.000291	CcSEcCtD
Sunitinib—ABCC2—testis—ovarian cancer	4.17e-05	0.000286	CbGeAlD
Sunitinib—Malnutrition—Epirubicin—ovarian cancer	4.16e-05	0.00029	CcSEcCtD
Sunitinib—Erythema—Epirubicin—ovarian cancer	4.16e-05	0.00029	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—ovarian cancer	4.13e-05	0.000288	CcSEcCtD
Sunitinib—Gastrointestinal pain—Docetaxel—ovarian cancer	4.11e-05	0.000287	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—ovarian cancer	4.1e-05	0.000286	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—ovarian cancer	4.1e-05	0.000286	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—ovarian cancer	4.1e-05	0.000285	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—ovarian cancer	4.07e-05	0.000284	CcSEcCtD
Sunitinib—Diarrhoea—Paclitaxel—ovarian cancer	4.06e-05	0.000283	CcSEcCtD
Sunitinib—Back pain—Epirubicin—ovarian cancer	4.02e-05	0.00028	CcSEcCtD
Sunitinib—KIT—lymph node—ovarian cancer	4.01e-05	0.000275	CbGeAlD
Sunitinib—Angiopathy—Doxorubicin—ovarian cancer	4.01e-05	0.000279	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—ovarian cancer	4e-05	0.000279	CcSEcCtD
Sunitinib—KCNH2—bone marrow—ovarian cancer	3.99e-05	0.000274	CbGeAlD
Sunitinib—Immune system disorder—Doxorubicin—ovarian cancer	3.99e-05	0.000278	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—ovarian cancer	3.98e-05	0.000278	CcSEcCtD
Sunitinib—Abdominal pain—Docetaxel—ovarian cancer	3.98e-05	0.000277	CcSEcCtD
Sunitinib—Body temperature increased—Docetaxel—ovarian cancer	3.98e-05	0.000277	CcSEcCtD
Sunitinib—Chills—Doxorubicin—ovarian cancer	3.96e-05	0.000276	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—ovarian cancer	3.95e-05	0.000275	CcSEcCtD
Sunitinib—Dizziness—Paclitaxel—ovarian cancer	3.92e-05	0.000274	CcSEcCtD
Sunitinib—PDGFRB—lymph node—ovarian cancer	3.92e-05	0.000269	CbGeAlD
Sunitinib—Alopecia—Doxorubicin—ovarian cancer	3.9e-05	0.000272	CcSEcCtD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—ovarian cancer	3.9e-05	0.01	CbGdCrCtD
Sunitinib—Mental disorder—Doxorubicin—ovarian cancer	3.87e-05	0.00027	CcSEcCtD
Sunitinib—KCNH2—female gonad—ovarian cancer	3.85e-05	0.000264	CbGeAlD
Sunitinib—Erythema—Doxorubicin—ovarian cancer	3.85e-05	0.000268	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—ovarian cancer	3.85e-05	0.000268	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—ovarian cancer	3.84e-05	0.000268	CcSEcCtD
Sunitinib—KCNH2—vagina—ovarian cancer	3.83e-05	0.000263	CbGeAlD
Sunitinib—Flatulence—Doxorubicin—ovarian cancer	3.79e-05	0.000264	CcSEcCtD
Sunitinib—Vomiting—Paclitaxel—ovarian cancer	3.77e-05	0.000263	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—ovarian cancer	3.77e-05	0.000263	CcSEcCtD
Sunitinib—Rash—Paclitaxel—ovarian cancer	3.74e-05	0.000261	CcSEcCtD
Sunitinib—Dermatitis—Paclitaxel—ovarian cancer	3.74e-05	0.000261	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—ovarian cancer	3.72e-05	0.000259	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—ovarian cancer	3.72e-05	0.000259	CcSEcCtD
Sunitinib—Headache—Paclitaxel—ovarian cancer	3.72e-05	0.000259	CcSEcCtD
Sunitinib—Hypersensitivity—Docetaxel—ovarian cancer	3.71e-05	0.000258	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—ovarian cancer	3.7e-05	0.000258	CcSEcCtD
Sunitinib—Cough—Epirubicin—ovarian cancer	3.63e-05	0.000253	CcSEcCtD
Sunitinib—Asthenia—Docetaxel—ovarian cancer	3.61e-05	0.000252	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—ovarian cancer	3.6e-05	0.000251	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—ovarian cancer	3.59e-05	0.00025	CcSEcCtD
Sunitinib—Pruritus—Docetaxel—ovarian cancer	3.56e-05	0.000248	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—ovarian cancer	3.55e-05	0.000248	CcSEcCtD
Sunitinib—ABCG2—bone marrow—ovarian cancer	3.55e-05	0.000244	CbGeAlD
Sunitinib—Chest pain—Epirubicin—ovarian cancer	3.54e-05	0.000247	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—ovarian cancer	3.54e-05	0.000247	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—ovarian cancer	3.54e-05	0.000247	CcSEcCtD
Sunitinib—Nausea—Paclitaxel—ovarian cancer	3.52e-05	0.000246	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.51e-05	0.000245	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—ovarian cancer	3.46e-05	0.000241	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—ovarian cancer	3.44e-05	0.00024	CcSEcCtD
Sunitinib—Diarrhoea—Docetaxel—ovarian cancer	3.44e-05	0.00024	CcSEcCtD
Sunitinib—ABCG2—female gonad—ovarian cancer	3.42e-05	0.000235	CbGeAlD
Sunitinib—KCNH2—testis—ovarian cancer	3.41e-05	0.000235	CbGeAlD
Sunitinib—ABCG2—vagina—ovarian cancer	3.4e-05	0.000234	CbGeAlD
Sunitinib—Oedema—Epirubicin—ovarian cancer	3.39e-05	0.000236	CcSEcCtD
Sunitinib—Infection—Epirubicin—ovarian cancer	3.37e-05	0.000235	CcSEcCtD
Sunitinib—Cough—Doxorubicin—ovarian cancer	3.36e-05	0.000234	CcSEcCtD
Sunitinib—Shock—Epirubicin—ovarian cancer	3.34e-05	0.000233	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—ovarian cancer	3.33e-05	0.000232	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—ovarian cancer	3.33e-05	0.000232	CcSEcCtD
Sunitinib—Dizziness—Docetaxel—ovarian cancer	3.33e-05	0.000232	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—ovarian cancer	3.32e-05	0.000232	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—ovarian cancer	3.32e-05	0.000231	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—ovarian cancer	3.29e-05	0.00023	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—ovarian cancer	3.27e-05	0.000228	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—ovarian cancer	3.27e-05	0.000228	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—ovarian cancer	3.27e-05	0.000228	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.25e-05	0.000227	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—ovarian cancer	3.23e-05	0.000225	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—ovarian cancer	3.2e-05	0.000223	CcSEcCtD
Sunitinib—Vomiting—Docetaxel—ovarian cancer	3.2e-05	0.000223	CcSEcCtD
Sunitinib—ABCB1—myometrium—ovarian cancer	3.18e-05	0.000219	CbGeAlD
Sunitinib—CYP3A5—female gonad—ovarian cancer	3.18e-05	0.000218	CbGeAlD
Sunitinib—Rash—Docetaxel—ovarian cancer	3.17e-05	0.000221	CcSEcCtD
Sunitinib—Dermatitis—Docetaxel—ovarian cancer	3.17e-05	0.000221	CcSEcCtD
Sunitinib—CYP3A5—vagina—ovarian cancer	3.16e-05	0.000217	CbGeAlD
Sunitinib—Headache—Docetaxel—ovarian cancer	3.15e-05	0.00022	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—ovarian cancer	3.14e-05	0.000219	CcSEcCtD
Sunitinib—ABCC4—lymph node—ovarian cancer	3.12e-05	0.000214	CbGeAlD
Sunitinib—Infection—Doxorubicin—ovarian cancer	3.12e-05	0.000217	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.09e-05	0.000215	CcSEcCtD
Sunitinib—Shock—Doxorubicin—ovarian cancer	3.09e-05	0.000215	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—ovarian cancer	3.08e-05	0.000215	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—ovarian cancer	3.07e-05	0.000214	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—ovarian cancer	3.07e-05	0.000214	CcSEcCtD
Sunitinib—ABCB1—embryo—ovarian cancer	3.06e-05	0.00021	CbGeAlD
Sunitinib—Skin disorder—Doxorubicin—ovarian cancer	3.05e-05	0.000213	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—ovarian cancer	3.05e-05	0.000212	CcSEcCtD
Sunitinib—ABCG2—testis—ovarian cancer	3.04e-05	0.000209	CbGeAlD
Sunitinib—Dyspnoea—Epirubicin—ovarian cancer	3.02e-05	0.000211	CcSEcCtD
Sunitinib—ABCC2—lymph node—ovarian cancer	3.02e-05	0.000207	CbGeAlD
Sunitinib—Anorexia—Doxorubicin—ovarian cancer	2.99e-05	0.000209	CcSEcCtD
Sunitinib—Nausea—Docetaxel—ovarian cancer	2.99e-05	0.000208	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—ovarian cancer	2.99e-05	0.000208	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—ovarian cancer	2.95e-05	0.000206	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	2.93e-05	0.000204	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—ovarian cancer	2.92e-05	0.000204	CcSEcCtD
Sunitinib—Constipation—Epirubicin—ovarian cancer	2.9e-05	0.000202	CcSEcCtD
Sunitinib—Pain—Epirubicin—ovarian cancer	2.9e-05	0.000202	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	2.86e-05	0.000199	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—ovarian cancer	2.84e-05	0.000198	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—ovarian cancer	2.82e-05	0.000196	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—ovarian cancer	2.8e-05	0.000195	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—ovarian cancer	2.77e-05	0.000193	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—ovarian cancer	2.76e-05	0.000193	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—ovarian cancer	2.73e-05	0.00019	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	2.71e-05	0.000189	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—ovarian cancer	2.71e-05	0.000189	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—ovarian cancer	2.68e-05	0.000187	CcSEcCtD
Sunitinib—Pain—Doxorubicin—ovarian cancer	2.68e-05	0.000187	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—ovarian cancer	2.68e-05	0.000187	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—ovarian cancer	2.68e-05	0.000187	CcSEcCtD
Sunitinib—CYP3A4—female reproductive system—ovarian cancer	2.62e-05	0.00018	CbGeAlD
Sunitinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.57e-05	0.000179	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—ovarian cancer	2.5e-05	0.000174	CcSEcCtD
Sunitinib—ABCB1—epithelium—ovarian cancer	2.5e-05	0.000172	CbGeAlD
Sunitinib—Abdominal pain—Doxorubicin—ovarian cancer	2.48e-05	0.000173	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—ovarian cancer	2.48e-05	0.000173	CcSEcCtD
Sunitinib—ABCB1—uterine cervix—ovarian cancer	2.48e-05	0.00017	CbGeAlD
Sunitinib—KCNH2—lymph node—ovarian cancer	2.47e-05	0.00017	CbGeAlD
Sunitinib—Asthenia—Epirubicin—ovarian cancer	2.43e-05	0.00017	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—ovarian cancer	2.4e-05	0.000167	CcSEcCtD
Sunitinib—ABCB1—decidua—ovarian cancer	2.36e-05	0.000162	CbGeAlD
Sunitinib—Diarrhoea—Epirubicin—ovarian cancer	2.32e-05	0.000162	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—ovarian cancer	2.31e-05	0.000161	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—ovarian cancer	2.25e-05	0.000157	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—ovarian cancer	2.24e-05	0.000156	CcSEcCtD
Sunitinib—ABCB1—endometrium—ovarian cancer	2.24e-05	0.000154	CbGeAlD
Sunitinib—Pruritus—Doxorubicin—ovarian cancer	2.22e-05	0.000155	CcSEcCtD
Sunitinib—ABCG2—lymph node—ovarian cancer	2.2e-05	0.000151	CbGeAlD
Sunitinib—Vomiting—Epirubicin—ovarian cancer	2.16e-05	0.00015	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—ovarian cancer	2.15e-05	0.00015	CcSEcCtD
Sunitinib—Rash—Epirubicin—ovarian cancer	2.14e-05	0.000149	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—ovarian cancer	2.14e-05	0.000149	CcSEcCtD
Sunitinib—Headache—Epirubicin—ovarian cancer	2.13e-05	0.000148	CcSEcCtD
Sunitinib—ABCB1—gonad—ovarian cancer	2.08e-05	0.000143	CbGeAlD
Sunitinib—Dizziness—Doxorubicin—ovarian cancer	2.08e-05	0.000145	CcSEcCtD
Sunitinib—ABCB1—uterus—ovarian cancer	2.06e-05	0.000142	CbGeAlD
Sunitinib—Nausea—Epirubicin—ovarian cancer	2.01e-05	0.00014	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—ovarian cancer	2e-05	0.000139	CcSEcCtD
Sunitinib—Rash—Doxorubicin—ovarian cancer	1.98e-05	0.000138	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—ovarian cancer	1.98e-05	0.000138	CcSEcCtD
Sunitinib—Headache—Doxorubicin—ovarian cancer	1.97e-05	0.000137	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—ovarian cancer	1.86e-05	0.00013	CcSEcCtD
Sunitinib—ABCB1—female reproductive system—ovarian cancer	1.86e-05	0.000127	CbGeAlD
Sunitinib—ABCB1—bone marrow—ovarian cancer	1.75e-05	0.00012	CbGeAlD
Sunitinib—ABCB1—female gonad—ovarian cancer	1.69e-05	0.000116	CbGeAlD
Sunitinib—ABCB1—vagina—ovarian cancer	1.68e-05	0.000115	CbGeAlD
Sunitinib—ABCB1—testis—ovarian cancer	1.5e-05	0.000103	CbGeAlD
Sunitinib—ABCB1—lymph node—ovarian cancer	1.09e-05	7.46e-05	CbGeAlD
Sunitinib—PDGFRB—Disease—PIK3CA—ovarian cancer	5.17e-07	2.63e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—ovarian cancer	5.17e-07	2.62e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CG—ovarian cancer	5.17e-07	2.62e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	5.17e-07	2.62e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—ovarian cancer	5.16e-07	2.62e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—ovarian cancer	5.16e-07	2.62e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—ovarian cancer	5.16e-07	2.62e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	5.15e-07	2.61e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK3—ovarian cancer	5.14e-07	2.61e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK3—ovarian cancer	5.14e-07	2.61e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	5.13e-07	2.61e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—PIK3CA—ovarian cancer	5.13e-07	2.61e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—ovarian cancer	5.13e-07	2.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—ovarian cancer	5.13e-07	2.61e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—ovarian cancer	5.13e-07	2.6e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—ovarian cancer	5.11e-07	2.59e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1B—ovarian cancer	5.11e-07	2.59e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—ovarian cancer	5.11e-07	2.59e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—ovarian cancer	5.1e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—ovarian cancer	5.1e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—ovarian cancer	5.1e-07	2.59e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	5.1e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—ovarian cancer	5.1e-07	2.59e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—ovarian cancer	5.09e-07	2.59e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	5.09e-07	2.58e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—ovarian cancer	5.08e-07	2.58e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—ovarian cancer	5.08e-07	2.58e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—ovarian cancer	5.08e-07	2.58e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CTNNB1—ovarian cancer	5.08e-07	2.58e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—ovarian cancer	5.07e-07	2.57e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—ovarian cancer	5.05e-07	2.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CTNNB1—ovarian cancer	5.05e-07	2.56e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MAPK1—ovarian cancer	5.05e-07	2.56e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—ovarian cancer	5.05e-07	2.56e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—ovarian cancer	5.05e-07	2.56e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—ovarian cancer	5.01e-07	2.54e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—ovarian cancer	5e-07	2.54e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—ovarian cancer	5e-07	2.54e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—ovarian cancer	5e-07	2.54e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—ovarian cancer	5e-07	2.54e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—PIK3CA—ovarian cancer	4.99e-07	2.53e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MAPK1—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—ovarian cancer	4.98e-07	2.53e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—ovarian cancer	4.97e-07	2.52e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—ovarian cancer	4.96e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—PIK3CA—ovarian cancer	4.96e-07	2.52e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—ovarian cancer	4.96e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—ovarian cancer	4.95e-07	2.51e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—ovarian cancer	4.95e-07	2.51e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—ovarian cancer	4.95e-07	2.51e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—ovarian cancer	4.92e-07	2.5e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—ovarian cancer	4.91e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—ovarian cancer	4.9e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK1—ovarian cancer	4.9e-07	2.49e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK1—ovarian cancer	4.9e-07	2.49e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—ovarian cancer	4.89e-07	2.48e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—ovarian cancer	4.89e-07	2.48e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK3—ovarian cancer	4.88e-07	2.48e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—ovarian cancer	4.87e-07	2.47e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	4.87e-07	2.47e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—ovarian cancer	4.85e-07	2.46e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CTNNB1—ovarian cancer	4.83e-07	2.45e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—ovarian cancer	4.8e-07	2.44e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—ovarian cancer	4.79e-07	2.43e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—ovarian cancer	4.78e-07	2.43e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—ovarian cancer	4.77e-07	2.42e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—ovarian cancer	4.77e-07	2.42e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—ovarian cancer	4.77e-07	2.42e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—ovarian cancer	4.76e-07	2.42e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—PIK3CA—ovarian cancer	4.76e-07	2.41e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—ovarian cancer	4.75e-07	2.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—ovarian cancer	4.75e-07	2.41e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—ovarian cancer	4.75e-07	2.41e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—PIK3CA—ovarian cancer	4.74e-07	2.41e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	4.74e-07	2.4e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—ovarian cancer	4.74e-07	2.4e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—ovarian cancer	4.73e-07	2.4e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—ovarian cancer	4.73e-07	2.4e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—ovarian cancer	4.71e-07	2.39e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—ovarian cancer	4.71e-07	2.39e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—ovarian cancer	4.7e-07	2.39e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—ovarian cancer	4.7e-07	2.39e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—ovarian cancer	4.69e-07	2.38e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—ovarian cancer	4.69e-07	2.38e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—ovarian cancer	4.69e-07	2.38e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—ovarian cancer	4.69e-07	2.38e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK1—ovarian cancer	4.65e-07	2.36e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—ovarian cancer	4.64e-07	2.36e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	4.64e-07	2.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	4.63e-07	2.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	4.63e-07	2.35e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—ovarian cancer	4.62e-07	2.35e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—ovarian cancer	4.62e-07	2.35e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—ovarian cancer	4.61e-07	2.34e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—ovarian cancer	4.6e-07	2.34e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—ovarian cancer	4.59e-07	2.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	4.59e-07	2.33e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	4.59e-07	2.33e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—ovarian cancer	4.59e-07	2.33e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—ovarian cancer	4.59e-07	2.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	4.58e-07	2.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—ovarian cancer	4.58e-07	2.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—ovarian cancer	4.58e-07	2.32e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—ovarian cancer	4.55e-07	2.31e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.54e-07	2.31e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	4.51e-07	2.29e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK3—ovarian cancer	4.5e-07	2.28e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—ovarian cancer	4.48e-07	2.27e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—ovarian cancer	4.47e-07	2.27e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—ovarian cancer	4.45e-07	2.26e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—FASN—ovarian cancer	4.44e-07	2.26e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—ovarian cancer	4.43e-07	2.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—ovarian cancer	4.42e-07	2.24e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—ovarian cancer	4.42e-07	2.24e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—ovarian cancer	4.41e-07	2.24e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—ovarian cancer	4.4e-07	2.24e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—ovarian cancer	4.4e-07	2.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—ovarian cancer	4.39e-07	2.23e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PIK3CA—ovarian cancer	4.38e-07	2.22e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	4.38e-07	2.22e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—ovarian cancer	4.37e-07	2.22e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.37e-07	2.22e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	4.36e-07	2.22e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—ovarian cancer	4.33e-07	2.2e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PIK3CA—ovarian cancer	4.33e-07	2.2e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CAV1—ovarian cancer	4.28e-07	2.17e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK1—ovarian cancer	4.28e-07	2.17e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—ovarian cancer	4.28e-07	2.17e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	4.27e-07	2.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—ovarian cancer	4.25e-07	2.16e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PIK3CA—ovarian cancer	4.25e-07	2.16e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	4.25e-07	2.16e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—ovarian cancer	4.24e-07	2.15e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK3—ovarian cancer	4.23e-07	2.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—ovarian cancer	4.23e-07	2.15e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.22e-07	2.14e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—ovarian cancer	4.21e-07	2.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—ovarian cancer	4.21e-07	2.14e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK3—ovarian cancer	4.21e-07	2.14e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—ovarian cancer	4.2e-07	2.13e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—ovarian cancer	4.2e-07	2.13e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—ovarian cancer	4.19e-07	2.13e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—ovarian cancer	4.18e-07	2.12e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	4.17e-07	2.12e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	4.17e-07	2.12e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	4.17e-07	2.12e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—ovarian cancer	4.11e-07	2.09e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—ovarian cancer	4.11e-07	2.09e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—ovarian cancer	4.11e-07	2.09e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—ovarian cancer	4.09e-07	2.08e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—ovarian cancer	4.07e-07	2.07e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—ovarian cancer	4.05e-07	2.06e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—ovarian cancer	4.05e-07	2.06e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.05e-07	2.05e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—ovarian cancer	4.04e-07	2.05e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PIK3CA—ovarian cancer	4.03e-07	2.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK1—ovarian cancer	4.02e-07	2.04e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—ovarian cancer	4.02e-07	2.04e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	4.02e-07	2.04e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK3—ovarian cancer	4.02e-07	2.04e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK1—ovarian cancer	4e-07	2.03e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—ovarian cancer	4e-07	2.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—ovarian cancer	4e-07	2.03e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	3.99e-07	2.03e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CB—ovarian cancer	3.96e-07	2.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	3.94e-07	2e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—ovarian cancer	3.93e-07	2e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—ovarian cancer	3.93e-07	2e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—ovarian cancer	3.91e-07	1.99e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—ovarian cancer	3.9e-07	1.98e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.9e-07	1.98e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	3.89e-07	1.97e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—ovarian cancer	3.89e-07	1.97e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—ovarian cancer	3.88e-07	1.97e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—ovarian cancer	3.87e-07	1.97e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—ovarian cancer	3.83e-07	1.94e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK1—ovarian cancer	3.83e-07	1.94e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—ovarian cancer	3.82e-07	1.94e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—ovarian cancer	3.8e-07	1.93e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—ovarian cancer	3.78e-07	1.92e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—ovarian cancer	3.76e-07	1.91e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—ovarian cancer	3.76e-07	1.91e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—ovarian cancer	3.73e-07	1.89e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	3.72e-07	1.89e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PIK3CA—ovarian cancer	3.71e-07	1.88e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	3.69e-07	1.87e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	3.62e-07	1.84e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—ovarian cancer	3.61e-07	1.83e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—ovarian cancer	3.59e-07	1.82e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.59e-07	1.82e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—ovarian cancer	3.58e-07	1.82e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—ovarian cancer	3.57e-07	1.81e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	3.56e-07	1.81e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—ovarian cancer	3.53e-07	1.79e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	3.5e-07	1.78e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PIK3CA—ovarian cancer	3.49e-07	1.77e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PIK3CA—ovarian cancer	3.47e-07	1.76e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—ovarian cancer	3.47e-07	1.76e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—ovarian cancer	3.47e-07	1.76e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—ovarian cancer	3.43e-07	1.74e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.43e-07	1.74e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—ovarian cancer	3.42e-07	1.74e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—ovarian cancer	3.38e-07	1.72e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	3.37e-07	1.71e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—ovarian cancer	3.36e-07	1.71e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	3.35e-07	1.7e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.34e-07	1.69e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.33e-07	1.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PIK3CA—ovarian cancer	3.32e-07	1.69e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—ovarian cancer	3.29e-07	1.67e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—ovarian cancer	3.29e-07	1.67e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	3.28e-07	1.67e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—ovarian cancer	3.27e-07	1.66e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—ovarian cancer	3.23e-07	1.64e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—ovarian cancer	3.21e-07	1.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—ovarian cancer	3.21e-07	1.63e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	3.21e-07	1.63e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—ovarian cancer	3.09e-07	1.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—ovarian cancer	3.08e-07	1.56e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—ovarian cancer	3.07e-07	1.56e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—ovarian cancer	3.03e-07	1.54e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.99e-07	1.52e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	2.96e-07	1.5e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—ovarian cancer	2.94e-07	1.49e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—ovarian cancer	2.85e-07	1.45e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—ovarian cancer	2.84e-07	1.44e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—ovarian cancer	2.75e-07	1.4e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—ovarian cancer	2.73e-07	1.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—ovarian cancer	2.71e-07	1.38e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CAV1—ovarian cancer	2.64e-07	1.34e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—ovarian cancer	2.58e-07	1.31e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.41e-07	1.23e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.4e-07	1.22e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.11e-07	1.07e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—ovarian cancer	1.97e-07	1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.84e-07	9.34e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.82e-07	9.25e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—ovarian cancer	1.59e-07	8.07e-07	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—ovarian cancer	1.49e-07	7.55e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.12e-07	5.7e-07	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—ovarian cancer	9.16e-08	4.65e-07	CbGpPWpGaD
